AstraZeneca (AZN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AZN Stock Forecast

AstraZeneca stock forecast is as follows: an average price target of $88.00 (represents a 34.66% upside from AZN’s last price of $65.35) and a rating consensus of 'Buy', based on 11 wall street analysts offering a 1-year stock forecast.

AZN Price Target

The average price target for AstraZeneca (AZN) is $88.00 based on 1-year price targets from 11 Wall Street analysts in the past 3 months, with a price target range of $88.00 to $88.00. This represents a potential 34.66% upside from AZN's last price of $65.35.

AZN Analyst Ratings

Buy

According to 11 Wall Street analysts, AstraZeneca's rating consensus is 'Buy'. The analyst rating breakdown for AZN stock is 0 'Strong Buy' (0.00%), 8 'Buy' (72.73%), 2 'Hold' (18.18%), 1 'Sell' (9.09%), and 0 'Strong Sell' (0.00%).

AstraZeneca Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	Etzer Darout	BMO Capital	$88.00	$81.19	8.39%	34.66%
Sep 11, 2024	Etzer Darout	BMO Capital	$89.00	$79.94	11.33%	36.19%
May 30, 2024	John Eade	Argus Research	$85.00	$76.84	10.62%	30.07%
May 28, 2024	Etzer Darout	BMO Capital	$82.00	$76.74	6.85%	25.48%
Jul 12, 2023	Andrew Berens	Leerink Partners	$79.00	$64.86	21.80%	20.89%
Jan 05, 2023		BMO Capital	$82.00	$69.50	17.99%	25.48%
Nov 11, 2022		Leerink Partners	$78.00	$65.09	19.83%	19.36%
May 04, 2022		Leerink Partners	$75.00	$67.17	11.66%	14.77%

The latest AstraZeneca stock forecast, released on Nov 13, 2024 by Etzer Darout from BMO Capital, set a price target of $88.00, which represents a 8.39% increase from the stock price at the time of the forecast ($81.19), and a 34.66% increase from AZN last price ($65.35).

AstraZeneca Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	4
Avg Price Target	-	$88.00	$86.00
Last Closing Price	$65.35	$65.35	$65.35
Upside/Downside	-100.00%	34.66%	31.60%

In the current month, the average price target of AstraZeneca stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AstraZeneca's last price of $65.35. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 13, 2024	Deutsche Bank	Sell	Hold	Downgrade
Sep 12, 2024	Deutsche Bank	Hold	Sell	Downgrade
Sep 11, 2024	BMO Capital	Outperform	Outperform	Hold
Sep 11, 2024	Nordea		Sell	Downgrade
Aug 12, 2024	Cowen & Co.	Buy	Buy	Hold
Jul 10, 2024	Barclays	Overweight	Overweight	Hold
Jul 02, 2024	Jefferies	Hold	Hold	Hold
May 30, 2024	Goldman Sachs		Buy	Initialise
May 28, 2024	BMO Capital	Outperform	Outperform	Hold
May 24, 2024	Morgan Stanley	Overweight	Overweight	Hold
May 22, 2024	Cowen & Co.	Buy	Buy	Hold
Apr 16, 2024	Deutsche Bank		Hold	Upgrade
Sep 25, 2023	Alliance Global Partners		Buy	Initialise
Sep 25, 2023	Jefferies		Buy	Upgrade
Jul 12, 2023	Argus Research	Buy	Buy	Hold
Apr 13, 2023	Argus Research	Buy	Buy	Hold
Jan 05, 2023	BMO Capital		Outperform	Initialise
Nov 11, 2022	SVB Leerink	Outperform	Outperform	Hold
Feb 24, 2022	SVB Leerink	Outperform	Outperform	Hold

AstraZeneca's last stock rating was published by BMO Capital on Nov 13, 2024. The company gave AZN a "Outperform" rating, the same as its previous rate.

AstraZeneca Financial Forecast

AstraZeneca Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	-	-	$10.88B	$11.21B	$10.98B	$10.77B	$11.39B	$12.01B	$9.87B	$8.22B	$7.32B	$7.41B	$6.58B	$6.28B	$6.35B	$6.66B	$6.41B	$5.82B	$5.49B	$5.18B	$5.41B
Avg Forecast	$14.78B	$14.50B	$14.04B	$13.76B	$14.15B	$13.08B	$12.62B	$11.80B	$12.08B	$11.55B	$11.01B	$10.60B	$11.25B	$10.79B	$10.45B	$10.81B	$11.11B	$9.52B	$7.44B	$6.98B	$7.12B	$6.61B	$6.22B	$5.91B	$6.73B	$6.13B	$5.59B	$5.38B	$6.70B	$4.05B
High Forecast	$14.94B	$14.66B	$14.20B	$13.82B	$14.52B	$13.08B	$12.62B	$11.91B	$12.26B	$11.88B	$11.14B	$10.72B	$11.38B	$10.79B	$10.45B	$10.81B	$11.11B	$9.52B	$7.44B	$6.98B	$7.12B	$6.61B	$6.22B	$5.91B	$6.73B	$6.13B	$5.59B	$5.38B	$8.04B	$4.86B
Low Forecast	$14.59B	$14.32B	$13.87B	$13.69B	$13.64B	$13.07B	$12.62B	$11.69B	$11.95B	$11.30B	$10.88B	$10.47B	$11.11B	$10.79B	$10.45B	$10.81B	$11.11B	$9.52B	$7.44B	$6.98B	$7.12B	$6.61B	$6.22B	$5.91B	$6.73B	$6.13B	$5.59B	$5.38B	$5.36B	$3.24B
# Analysts	1	1	1	1	6	3	2	2	4	4	2	2	1	1	1	1	2	2	2	2	2	10	10	10	9	9	9	9	20	10
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.03%	1.00%	1.02%	1.03%	1.05%	1.08%	1.04%	1.10%	1.05%	1.04%	1.00%	1.01%	1.07%	0.99%	1.05%	1.04%	1.02%	0.77%	1.33%

AstraZeneca's average Quarter revenue forecast for Jun 23 based on 2 analysts is $11.01B, with a low forecast of $10.88B, and a high forecast of $11.14B. AZN's average Quarter revenue forecast represents a 1.22% increase compared to the company's last Quarter revenue of $10.88B (Mar 23).

AstraZeneca EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	6	3	2	2	4	4	2	2	1	1	1	1	2	2	2	2	2	10	10	10	9	9	9	9	20	10
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$3.89B	$1.14B	$2.76B	$1.92B	$2.20B	$1.87B	$1.12B	$1.84B	$2.71B	$2.26B	$1.98B	$2.02B	$2.14B	$2.24B	$1.50B	$1.25B	$1.83B	$1.45B	$1.60B
Avg Forecast	$3.28B	$3.22B	$3.12B	$3.06B	$3.14B	$2.91B	$2.81B	$2.38B	$2.69B	$2.57B	$2.45B	$2.16B	$1.87B	$2.84B	$2.76B	$1.97B	$2.93B	$2.51B	$1.96B	$2.45B	$1.88B	$1.74B	$1.64B	$1.87B	$1.77B	$1.62B	$1.47B	$1.70B	$1.88B	$1.20B
High Forecast	$3.32B	$3.26B	$3.16B	$3.07B	$3.23B	$2.91B	$2.81B	$2.85B	$2.73B	$2.64B	$2.48B	$2.60B	$2.24B	$2.84B	$2.76B	$2.36B	$2.93B	$2.51B	$1.96B	$2.95B	$1.88B	$1.74B	$1.64B	$2.24B	$1.77B	$1.62B	$1.47B	$2.04B	$2.25B	$1.44B
Low Forecast	$3.24B	$3.18B	$3.08B	$3.04B	$3.03B	$2.91B	$2.81B	$1.90B	$2.66B	$2.51B	$2.42B	$1.73B	$1.49B	$2.84B	$2.76B	$1.57B	$2.93B	$2.51B	$1.96B	$1.96B	$1.88B	$1.74B	$1.64B	$1.49B	$1.77B	$1.62B	$1.47B	$1.36B	$1.50B	$963.00M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.80%	0.61%	0.97%	0.69%	1.12%	0.64%	0.45%	0.94%	1.10%	1.20%	1.13%	1.23%	1.15%	1.26%	0.93%	0.85%	1.08%	0.77%	1.33%

2 analysts predict AZN's average Quarter EBITDA for Jun 23 to be $2.45B, with a high of $2.48B and a low of $2.42B. This is -37.03% lower than AstraZeneca's previous annual EBITDA (Mar 23) of $3.89B.

AstraZeneca Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	6	3	2	2	4	4	2	2	1	1	1	1	2	2	2	2	2	10	10	10	9	9	9	9	20	10
Net Income	-	-	-	-	-	-	-	-	-	-	-	$1.80B	$901.00M	$1.64B	$360.00M	$386.00M	$-346.00M	$-1.65B	$550.00M	$1.56B	$1.01B	$648.00M	$756.00M	$780.00M	$313.00M	$299.00M	$130.00M	$593.00M	$340.00M	$537.00M
Avg Forecast	$3.30B	$3.84B	$3.54B	$3.65B	$3.32B	$3.19B	$3.07B	$418.18M	$2.28B	$2.63B	$3.09B	$380.17M	$-347.00M	$2.37B	$2.44B	$345.60M	$2.40B	$1.94B	$1.38B	$1.42B	$1.72B	$1.55B	$1.42B	$680.43M	$1.55B	$1.49B	$914.41M	$550.64M	$440.00M	$402.75M
High Forecast	$3.35B	$3.89B	$3.59B	$3.70B	$3.79B	$3.24B	$3.07B	$501.82M	$2.65B	$2.67B	$3.13B	$456.20M	$-277.60M	$2.37B	$2.44B	$414.73M	$2.40B	$1.94B	$1.38B	$1.70B	$1.72B	$1.55B	$1.42B	$816.51M	$1.55B	$1.49B	$914.41M	$660.77M	$528.00M	$483.30M
Low Forecast	$3.25B	$3.77B	$3.48B	$3.61B	$3.04B	$3.14B	$3.07B	$334.55M	$2.10B	$2.59B	$3.04B	$304.13M	$-416.40M	$2.37B	$2.44B	$276.48M	$2.40B	$1.94B	$1.38B	$1.13B	$1.72B	$1.55B	$1.42B	$544.34M	$1.55B	$1.49B	$914.41M	$440.51M	$352.00M	$322.20M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	4.74%	-2.60%	0.69%	0.15%	1.12%	-0.14%	-0.85%	0.40%	1.10%	0.59%	0.42%	0.53%	1.15%	0.20%	0.20%	0.14%	1.08%	0.77%	1.33%

AstraZeneca's average Quarter net income forecast for Jun 23 is $3.09B, with a range of $3.04B to $3.13B. AZN's average Quarter net income forecast represents a 71.20% increase compared to the company's last Quarter net income of $1.80B (Mar 23).

AstraZeneca SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	6	3	2	2	4	4	2	2	1	1	1	1	2	2	2	2	2	10	10	10	9	9	9	9	20	10
SG&A	-	-	-	-	-	-	-	-	-	-	-	$4.19B	$4.78B	$3.29B	$4.81B	$4.96B	$7.53B	$2.99B	$3.20B	$3.03B	$5.08B	$2.27B	$2.74B	$2.81B	$1.97B	$3.25B	$3.02B	$2.59B	$2.54B	$4.68B
Avg Forecast	$6.40B	$6.28B	$6.08B	$5.96B	$6.13B	$5.66B	$5.47B	$5.38B	$5.23B	$5.00B	$4.77B	$4.89B	$7.53B	$4.68B	$4.54B	$4.45B	$4.82B	$4.13B	$3.23B	$2.75B	$3.09B	$2.87B	$2.70B	$2.45B	$2.92B	$2.66B	$2.42B	$2.41B	$3.28B	$3.51B
High Forecast	$6.47B	$6.35B	$6.15B	$5.98B	$6.29B	$5.66B	$5.47B	$6.45B	$5.31B	$5.15B	$4.82B	$5.87B	$9.03B	$4.68B	$4.54B	$5.33B	$4.82B	$4.13B	$3.23B	$3.29B	$3.09B	$2.87B	$2.70B	$2.94B	$2.92B	$2.66B	$2.42B	$2.89B	$3.94B	$4.21B
Low Forecast	$6.32B	$6.20B	$6.00B	$5.93B	$5.91B	$5.66B	$5.47B	$4.30B	$5.17B	$4.89B	$4.71B	$3.91B	$6.02B	$4.68B	$4.54B	$3.56B	$4.82B	$4.13B	$3.23B	$2.20B	$3.09B	$2.87B	$2.70B	$1.96B	$2.92B	$2.66B	$2.42B	$1.93B	$2.63B	$2.81B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.86%	0.63%	0.70%	1.06%	1.12%	1.56%	0.72%	0.99%	1.10%	1.64%	0.79%	1.02%	1.15%	0.67%	1.22%	1.25%	1.08%	0.77%	1.33%

AstraZeneca's average Quarter SG&A projection for Jun 23 is $4.77B, based on 2 Wall Street analysts, with a range of $4.71B to $4.82B. The forecast indicates a 13.73% rise compared to AZN last annual SG&A of $4.19B (Mar 23).

AstraZeneca EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	1	6	3	2	2	4	4	2	2	1	1	1	1	2	2	2	2	2	10	10	10	9	9	9	9	20	10
EPS	-	-	-	-	-	-	-	-	-	-	-	$0.58	$0.29	$0.53	$0.12	$0.13	$-0.11	$-0.55	$0.21	$0.60	$0.39	$0.25	$0.29	$0.30	$0.12	$0.12	$0.04	$0.24	$0.14	$0.21
Avg Forecast	$1.06	$1.23	$1.13	$1.17	$1.06	$1.02	$0.98	$0.96	$0.73	$0.84	$0.99	$0.85	$0.67	$0.76	$0.78	$0.85	$0.77	$0.62	$0.44	$0.71	$0.55	$0.50	$0.46	$0.45	$0.50	$0.48	$0.29	$0.42	$0.44	$0.30
High Forecast	$1.07	$1.25	$1.15	$1.18	$1.21	$1.04	$0.98	$0.96	$0.85	$0.86	$1.00	$0.87	$0.68	$0.76	$0.78	$0.85	$0.77	$0.62	$0.44	$0.71	$0.55	$0.50	$0.46	$0.45	$0.50	$0.48	$0.29	$0.42	$0.53	$0.36
Low Forecast	$1.04	$1.21	$1.12	$1.16	$0.97	$1.00	$0.98	$0.95	$0.67	$0.83	$0.97	$0.84	$0.66	$0.76	$0.78	$0.85	$0.77	$0.62	$0.44	$0.71	$0.55	$0.50	$0.46	$0.45	$0.50	$0.48	$0.29	$0.42	$0.35	$0.24
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.68%	0.43%	0.70%	0.15%	0.15%	-0.14%	-0.88%	0.47%	0.85%	0.71%	0.50%	0.64%	0.66%	0.24%	0.25%	0.15%	0.57%	0.32%	0.70%

According to 2 Wall Street analysts, AstraZeneca's projected average Quarter EPS for Jun 23 is $0.99, with a low estimate of $0.97 and a high estimate of $1.00. This represents a 70.35% increase compared to AZN previous annual EPS of $0.58 (Mar 23).

AstraZeneca Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
GSK	GSK	$34.23	$53.00	54.83%	Hold
MRK	Merck	$100.06	$135.83	35.75%	Buy
LLY	Eli Lilly and Company	$778.62	$1.03K	31.80%	Buy
AZN	AstraZeneca	$67.18	$88.00	30.99%	Buy
AMGN	Amgen	$265.95	$338.22	27.17%	Buy
SNY	Sanofi	$48.94	$62.00	26.69%	Buy
PFE	Pfizer	$26.43	$32.83	24.21%	Hold
NVS	Novartis	$99.10	$120.50	21.59%	Hold
ABBV	AbbVie	$175.38	$211.20	20.42%	Buy
JNJ	Johnson & Johnson	$146.41	$175.13	19.62%	Buy
GILD	Gilead Sciences	$92.80	$87.30	-5.93%	Buy
BMY	Bristol-Myers Squibb Company	$57.65	$50.50	-12.40%	Hold

AZN Forecast FAQ

Is AstraZeneca a good buy?

Yes, according to 11 Wall Street analysts, AstraZeneca (AZN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 72.73% of AZN's total ratings.

What is AZN's price target?

AstraZeneca (AZN) average price target is $88 with a range of $88 to $88, implying a 34.66% from its last price of $65.35. The data is based on 11 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will AstraZeneca stock go up soon?

According to Wall Street analysts' prediction for AZN stock, the company can go up by 34.66% (from the last price of $65.35 to the average price target of $88), up by 34.66% based on the highest stock price target, and up by 34.66% based on the lowest stock price target.

Can AstraZeneca stock reach $100?

AZN's average twelve months analyst stock price target of $88 does not support the claim that AstraZeneca can reach $100 in the near future.

What are AstraZeneca's analysts' financial forecasts?

AstraZeneca's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $51.64B (high $52.13B, low $51.02B), average EBITDA is $11.24B (high $11.8B, low $10.65B), average net income is $10B (high $10.61B, low $9.58B), average SG&A $22.63B (high $23.87B, low $21.34B), and average EPS is $4.02 (high $4.2, low $3.91). AZN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $57.07B (high $57.62B, low $56.47B), average EBITDA is $12.69B (high $12.81B, low $12.55B), average net income is $14.32B (high $14.53B, low $14.12B), average SG&A $24.71B (high $24.95B, low $24.45B), and average EPS is $4.58 (high $4.65, low $4.52).

Did the AZN's actual financial results beat the analysts' financial forecasts?

Based on AstraZeneca's last annual report (Dec 2022), the company's revenue was $44.35B, beating the average analysts forecast of $43.3B by 2.42%. Apple's EBITDA was $9.33B, missing the average prediction of $9.43B by -1.14%. The company's net income was $3.29B, missing the average estimation of $4.81B by -31.61%. Apple's SG&A was $18.96B, missing the average forecast of $21.19B by -10.54%. Lastly, the company's EPS was $1.06, missing the average prediction of $3.06 by -65.36%. In terms of the last quarterly report (Mar 2023), AstraZeneca's revenue was $10.88B, beating the average analysts' forecast of $10.6B by 2.59%. The company's EBITDA was $3.89B, beating the average prediction of $2.16B by 79.77%. AstraZeneca's net income was $1.8B, beating the average estimation of $380.17M by 374.27%. The company's SG&A was $4.19B, missing the average forecast of $4.89B by -14.25%. Lastly, the company's EPS was $0.58, missing the average prediction of $0.854 by -32.06%